Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.
|Articles|September 1, 2001
PDT offers good response, recurrence rates for multiple BCCs
Vancouver, Canada - ALA-PDT is the treatment of choice for patients with multiple superficial basal cell carcinomas on the face, trunk, or scalp, particularly because of its excellent cosmetic results, Willem Star, Ph.D., said at the World Congress of Photodynamic Therapy.
Advertisement
Advertisement
Related to this article
The September issue highlights advances in alopecia areata, cosmetic SPF, psoriasis treatment, teledermatology, and atopic dermatitis.
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Lutikizumab significantly improved HiSCR75 response, pain, and disease flares in adults and adolescents with moderate to severe HS.
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
Advertisement
Advertisement
Trending on Dermatology Times
1
Lutikizumab Meets Primary End Point in Phase 3 HS Trial
2
Tolerability and Response Criteria Guide Hedgehog Inhibitor Choice in Advanced BCC
3
Dupilumab Associated With Lower Atopic March Risk in Pediatric Atopic Dermatitis
4
AAD, HS Foundation Issue First Joint Hidradenitis Suppurativa Guidelines
5